Corrigendum to "Do PHI and PHI density improve detection of clinically significant prostate cancer only in the PSA gray zone?" [Clin. Chim. Acta 542 (2023) 117270]

Affiliations

¹ Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Urology, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Department of Surgery, Radiology and Physical Medicine, University of the Basque Country (UPV/EHU), Leioa, Spain. Electronic address: leire.riusbilbao@osakidetza.eus.
² Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Clinical Laboratory Medicine, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
³ Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Research Unit, Spain.
⁴ IMQ Zorrotzaurre Hospital, Department of Urology, Spain.
⁵ Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Urology, Spain.
⁶ Osakidetza Basque Health Service, Barakaldo-Sestao Integrated Health Organisation, Department of Urology, Spain.
⁷ Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Department of Urology, Spain.
⁸ Osakidetza Basque Health Service, Debagoiena Integrated Health Organisation, Research Unit, Spain; Biodonostia Health Research Institute, Donostia-San Sebastián, Spain; Kronikgune Institute for Health Services Research, Barakaldo, Spain.

Published Erratum

Leire Rius Bilbao et al. Clin Chim Acta. 2026.

. 2026 Jan 15:579:120590.

doi: 10.1016/j.cca.2025.120590. Epub 2025 Sep 16.

¹ Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Urology, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Department of Surgery, Radiology and Physical Medicine, University of the Basque Country (UPV/EHU), Leioa, Spain. Electronic address: leire.riusbilbao@osakidetza.eus.
² Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Clinical Laboratory Medicine, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
³ Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Research Unit, Spain.
⁴ IMQ Zorrotzaurre Hospital, Department of Urology, Spain.
⁵ Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Urology, Spain.
⁶ Osakidetza Basque Health Service, Barakaldo-Sestao Integrated Health Organisation, Department of Urology, Spain.
⁷ Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Department of Urology, Spain.
⁸ Osakidetza Basque Health Service, Debagoiena Integrated Health Organisation, Research Unit, Spain; Biodonostia Health Research Institute, Donostia-San Sebastián, Spain; Kronikgune Institute for Health Services Research, Barakaldo, Spain.

No abstract available

Erratum for

Do PHI and PHI density improve detection of clinically significant prostate cancer only in the PSA gray zone?
Rius Bilbao L, Valladares Gomez C, Aguirre Larracoechea U, Pereira Arias JG, Arredondo Calvo P, Urdaneta Salegui LF, Escobal Tamayo V, Sanz Jaka JP, Recio Ayesa A, Mar Medina J, Mar Medina C. Rius Bilbao L, et al. Clin Chim Acta. 2023 Mar 1;542:117270. doi: 10.1016/j.cca.2023.117270. Epub 2023 Mar 7. Clin Chim Acta. 2023. PMID: 36893880